What is the difference between WIPO Standard ST.25 and ST.26 for Sequence Listings?
WIPO Standard ST.25 and ST.26 are two different formats for submitting Sequence Listings in patent applications. The key differences are: ST.25 is the older format, used for applications filed before July 1, 2022. ST.26 is the new XML-based format, required for applications filed on or after July 1, 2022. The MPEP explains the transition: “Though…
Read MoreHow does the Sequence Listing XML requirement affect applications claiming priority to earlier filings?
Applications filed on or after July 1, 2022, that claim benefit or priority to earlier applications must still comply with the new Sequence Listing XML requirement, regardless of the format used in the prior application. The MPEP clarifies: “If a prior application to which benefit or priority is claimed contains a ‘Sequence Listing’ in Standard…
Read MoreHow should ambiguity in sequences be represented in a sequence listing?
How should ambiguity in sequences be represented in a sequence listing? Ambiguity in sequences should be represented using specific symbols and annotations as outlined in MPEP 2423.01 and WIPO Standard ST.25. Here’s how to handle ambiguous positions: For nucleotides: Use “n” to represent an unknown or ambiguous base For amino acids: Use “Xaa” to represent…
Read MoreWhat symbols should be used for representing nucleotides in a sequence listing?
The MPEP 2423.01 specifies the symbols to be used for representing nucleotides in a sequence listing: “The bases in nucleotide sequences must be represented using the one-letter code for nucleotide sequence characters. Only lower case letters in conformity with the list given in WIPO Standard ST.25 (1998), Appendix 2, Table 1, may be used.” The…
Read MoreHow are nucleotide bases represented in a sequence listing?
How are nucleotide bases represented in a sequence listing? Nucleotide bases in a sequence listing are represented using specific symbols as outlined in WIPO Standard ST.25 and referenced in MPEP 2423.01. The representation follows these guidelines: Use the one-letter code for nucleotide sequence bases: A, C, G, T for DNA; A, C, G, U for…
Read MoreWhat are the key components of a sequence listing?
According to MPEP 2412.01, a sequence listing must contain the following key components: A separate sequence for each sequence disclosed in the application Use of the symbols set forth in WIPO Standard ST.25 (1998) A unique identifier for each sequence (SEQ ID NO:) Separate presentation of nucleotides and amino acids Enumeration of nucleotides and amino…
Read MoreWhat is the proper format for presenting sequences in a patent application?
What is the proper format for presenting sequences in a patent application? The proper format for presenting sequences in a patent application is outlined in MPEP 2423.01 and follows the WIPO Standard ST.25. Key points include: Use a fixed-width font (e.g., Courier) in 10 point or larger size Present sequences with a maximum of 60…
Read MoreWhat symbols are used for amino acids in a sequence listing?
What symbols are used for amino acids in a sequence listing? In a sequence listing, amino acids are represented using specific symbols as defined by WIPO Standard ST.25. According to MPEP 2423.01: “The amino acids in a protein or peptide sequence must be represented using the three-letter abbreviation with the first letter as a capital.”…
Read MoreHow should ambiguity symbols be used in nucleotide sequences?
The MPEP 2423.01 provides guidance on using ambiguity symbols in nucleotide sequences: “For those nucleotides that are ambiguous in designation, the list of one-letter codes given in WIPO Standard ST.25 (1998), Appendix 2, Table 2, must be used.” Some common ambiguity symbols include: n – a or c or g or t/u r – a…
Read More